Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Gene Therapy for Neurodegenerative Diseases
1.2 Key Market Segments
1.2.1 Gene Therapy for Neurodegenerative Diseases Segment by Type
1.2.2 Gene Therapy for Neurodegenerative Diseases Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Gene Therapy for Neurodegenerative Diseases Market Overview
2.1 Global Market Overview
2.1.1 Global Gene Therapy for Neurodegenerative Diseases Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Gene Therapy for Neurodegenerative Diseases Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Gene Therapy for Neurodegenerative Diseases Market Competitive Landscape
3.1 Global Gene Therapy for Neurodegenerative Diseases Sales by Manufacturers (2019-2024)
3.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Manufacturers (2019-2024)
3.3 Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Gene Therapy for Neurodegenerative Diseases Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Gene Therapy for Neurodegenerative Diseases Sales Sites, Area Served, Product Type
3.6 Gene Therapy for Neurodegenerative Diseases Market Competitive Situation and Trends
3.6.1 Gene Therapy for Neurodegenerative Diseases Market Concentration Rate
3.6.2 Global 5 and 10 Largest Gene Therapy for Neurodegenerative Diseases Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Gene Therapy for Neurodegenerative Diseases Industry Chain Analysis
4.1 Gene Therapy for Neurodegenerative Diseases Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Gene Therapy for Neurodegenerative Diseases Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Gene Therapy for Neurodegenerative Diseases Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Gene Therapy for Neurodegenerative Diseases Sales Market Share by Type (2019-2024)
6.3 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2019-2024)
6.4 Global Gene Therapy for Neurodegenerative Diseases Price by Type (2019-2024)
7 Gene Therapy for Neurodegenerative Diseases Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Gene Therapy for Neurodegenerative Diseases Market Sales by Application (2019-2024)
7.3 Global Gene Therapy for Neurodegenerative Diseases Market Size (M USD) by Application (2019-2024)
7.4 Global Gene Therapy for Neurodegenerative Diseases Sales Growth Rate by Application (2019-2024)
8 Gene Therapy for Neurodegenerative Diseases Market Segmentation by Region
8.1 Global Gene Therapy for Neurodegenerative Diseases Sales by Region
8.1.1 Global Gene Therapy for Neurodegenerative Diseases Sales by Region
8.1.2 Global Gene Therapy for Neurodegenerative Diseases Sales Market Share by Region
8.2 North America
8.2.1 North America Gene Therapy for Neurodegenerative Diseases Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Gene Therapy for Neurodegenerative Diseases Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Gene Therapy for Neurodegenerative Diseases Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Gene Therapy for Neurodegenerative Diseases Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Gene Therapy for Neurodegenerative Diseases Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Voyager Therapeutics
9.1.1 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Basic Information
9.1.2 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Overview
9.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.1.4 Voyager Therapeutics Business Overview
9.1.5 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases SWOT Analysis
9.1.6 Voyager Therapeutics Recent Developments
9.2 Uniqure N.V.
9.2.1 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Basic Information
9.2.2 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Overview
9.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.2.4 Uniqure N.V. Business Overview
9.2.5 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases SWOT Analysis
9.2.6 Uniqure N.V. Recent Developments
9.3 Axovant Gene Therapies
9.3.1 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Basic Information
9.3.2 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Overview
9.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases SWOT Analysis
9.3.5 Axovant Gene Therapies Business Overview
9.3.6 Axovant Gene Therapies Recent Developments
9.4 Novartis Ag
9.4.1 Novartis Ag Gene Therapy for Neurodegenerative Diseases Basic Information
9.4.2 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Overview
9.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.4.4 Novartis Ag Business Overview
9.4.5 Novartis Ag Recent Developments
9.5 Amicus Therapeutics
9.5.1 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Basic Information
9.5.2 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Overview
9.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.5.4 Amicus Therapeutics Business Overview
9.5.5 Amicus Therapeutics Recent Developments
9.6 Regenxbio Inc.
9.6.1 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Basic Information
9.6.2 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Overview
9.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.6.4 Regenxbio Inc. Business Overview
9.6.5 Regenxbio Inc. Recent Developments
9.7 Sarepta Therapeutics
9.7.1 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Basic Information
9.7.2 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Overview
9.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.7.4 Sarepta Therapeutics Business Overview
9.7.5 Sarepta Therapeutics Recent Developments
9.8 Gensight Biologics
9.8.1 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Basic Information
9.8.2 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Overview
9.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.8.4 Gensight Biologics Business Overview
9.8.5 Gensight Biologics Recent Developments
9.9 Krystal Biotech
9.9.1 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Basic Information
9.9.2 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Overview
9.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.9.4 Krystal Biotech Business Overview
9.9.5 Krystal Biotech Recent Developments
9.10 Avexis
9.10.1 Avexis Gene Therapy for Neurodegenerative Diseases Basic Information
9.10.2 Avexis Gene Therapy for Neurodegenerative Diseases Product Overview
9.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Product Market Performance
9.10.4 Avexis Business Overview
9.10.5 Avexis Recent Developments
10 Gene Therapy for Neurodegenerative Diseases Market Forecast by Region
10.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast
10.2 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Country
10.2.3 Asia Pacific Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Region
10.2.4 South America Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Gene Therapy for Neurodegenerative Diseases by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Gene Therapy for Neurodegenerative Diseases by Type (2025-2030)
11.1.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Gene Therapy for Neurodegenerative Diseases by Type (2025-2030)
11.2 Global Gene Therapy for Neurodegenerative Diseases Market Forecast by Application (2025-2030)
11.2.1 Global Gene Therapy for Neurodegenerative Diseases Sales (K Units) Forecast by Application
11.2.2 Global Gene Therapy for Neurodegenerative Diseases Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
